# A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

> **NCT00968981** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** GDC-0449
- **DRUG:** GDC-0449
- **DRUG:** GDC-0449

## Key facts

- **NCT ID:** NCT00968981
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00968981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00968981, "A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00968981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*